Evidence map›Paper›PMID 40515634›Full record

ArticleAmerican journal of medical genetics. Part A2025

Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function MECP2 Variants.

Talia Thompson, Dennis Gurfinkel, Lori Silveira, Natalia Klamut, Kate Ferdinandsen, Cary Fu, Amitha L Ananth, Jane B Lane, Eric D Marsh, Jeffrey L Neul and 2 more

Abstract read
In one paragraph

Article in American journal of medical genetics. Part A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Talia ThompsonPediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.
Dennis GurfinkelAccords, University of Colorado School of Medicine, Aurora, Colorado, USA.
Lori SilveiraPediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.
Natalia KlamutPediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.ORCID 0009-0004-9966-0160
Kate Ferdinandsen
Cary FuPediatrics, Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Amitha L AnanthPediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-9671-2883
Jane B LanePediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Eric D MarshUniversity of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Jeffrey L NeulPediatrics, Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Alan K PercyPediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Timothy A BenkePediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.

Funding

Training and Career Development ComponentU54HD061222 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PERCY, ALAN KENNETH · 2009 to 2019
$12.4M
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
International Rett Syndrome FoundationNICHD NIH HHS P50 HD103537NICHD NIH HHS U54 HD061222Rocky Mountain Rett Association
6 · The paper itself

Abstract

Rett syndrome (RTT) is a rare neurodevelopmental disorder typically caused by loss-of-function variants in the transcriptional regulator methyl-CpG binding protein-2 (MECP2) gene. These variants were historically believed to be incompatible with life in males; however, recent advances in genetic testing have revealed significant clinical heterogeneity. The current study aimed to improve our understanding of diagnostic experiences in males with confirmed pathogenic alteration of MECP2. An international sample of caregivers completed a survey of diagnostic experiences (N = 47) and phenomenological interviews (n = 32). Median [interquartile range; IQR] age of genetic diagnosis was 3 years [1.08, 6.75]. Multivariate analysis showed that for every year increase in year of birth, age of diagnosis (in years) decreased by 0.31. Qualitative findings demonstrate that medical biases and widespread misconceptions contribute to delays in accurate clinical diagnosis, which negatively impacts child health and family functioning. As genetic testing becomes more widely available, age of genetic diagnosis is decreasing, resulting in more providers and families with unexpected results and a notable lack of male-specific anticipatory guidance and clinical recommendations. Diagnostic providers must increase their awareness of males with confirmed pathogenic alterations of MECP2 and be prepared to deliver the diagnosis with empathy and accurate, up-to-date information on prognosis and treatment options.

Indexed as

Loss of Function MutationMethyl-CpG-Binding Protein 2Rett SyndromeBiasCaregiversChildChild, PreschoolDelayed DiagnosisGenetic TestingHumansInfantMaleSurveys and QuestionnairesMECP2 protein, humanMethyl-CpG-Binding Protein 2diagnostic experienceMECP2mixed methodsphenomenologyRett syndrome

Identifiers

PMID40515634
PMCPMC12232454

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.